Video Education and Behaviour Contract to Optimize Adherence in Renal Transplants (VECTOR)

August 14, 2024 updated by: Holly Mansell, University of Saskatchewan

Improving Adherence in Kidney Recipients: a Randomized Controlled Trial of a Post-transplant Education Intervention

This study aims to test the effectiveness of an electronic-based video intervention and behavioral contract on improving medication adherence among kidney transplant recipients.

Study Overview

Detailed Description

Non-adherence to immunosuppressive medications is a major problem after kidney transplantation, leading to increased rejections, hospitalizations and health care expenditures. Effective educational opportunities may positively influence adherence, especially when combined with a behavior intervention. However, increasing education and support to transplant recipients demands greater use of care providers' time and resources in a health care system that is already stretched.

A patient-oriented video series has been developed according to best practices for transplant education, featuring an animated character embarking on a transplant journey. Animated segments illustrate difficult concepts for patients with poor health literacy, and patient narratives provide support and encouragement. A multicenter randomized controlled trial will be conducted with 4 sites across North America. Patients will be randomized (1:1) to either the intervention (i.e., home-based video education + adherence contract plus usual care) or usual care alone. Patients will be enrolled in the study prior to hospital discharge and will be provided with access to the video intervention and contract electronically. The primary outcome will be adherence at 12 months post-transplant, as measured by self-report (BAASIS), and variability in immunosuppressant levels. Secondary outcomes include the change in knowledge score between the intervention and control in groups (measured by the Kidney Transplant Understanding Tool); differences in self-efficacy (Generalized Self-efficacy Scale), beliefs about medicines (Beliefs of Medicine Questionnaire), and quality of life (SF-12). Individualized viewing statistics will be analyzed to determine patient uptake, and satisfaction about the educational experience will be captured on a self-reported survey.

Study Type

Interventional

Enrollment (Actual)

173

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alberta
      • Calgary, Alberta, Canada
        • Southern Alberta Transplant Program
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada
        • Saskatchewan Transplant Program
    • Illinois
      • Chicago, Illinois, United States, 60612
        • University of Illinois Health Sciences System

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • 18 or older
  • can speak and understand and read English
  • receive their first kidney transplant at one of the participating sites during enrolment

Exclusion Criteria:

  • do not meet inclusion criteria
  • have previously participated in a study entitle "Improving health outcomes of kidney recipients: A randomized controlled trial of a pre-transplant education intervention"

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Video education + adherence contract
electronically delivered video education (at transplant discharge) + electronic adherence contract (1 month after enrolment)
Participants will receive standard education along with the home-based video education plus an adherence contract. Following the baseline assessment, access to videos will be provided electronically so that the patient can watch them at home. The videos will be initially viewed in the following order: Video 1: Introduction, Video 2: Medications, Video 3: Your New Life. Approximately one month after transplant, after the video series has been viewed in its entirety, participants will receive an email link inviting participants to reflect on their goals about transplantation and pledging to taking their medications as directed. The contract will be non-enforceable, but it will provide patients with the opportunity to formally commit to a goal of taking the medications as prescribed. At 3 months, and 12 months, the participant will have the opportunity to reflect and modify adherence goals as desired.
Other Names:
  • Solid Organ Transplantation: An Educational Mini-Series for Patients
No Intervention: Standard education
standard of care education provided at each transplant center (control emails will be provided at intervention time points)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in adherence to immunosuppressant medications between intervention and control (self-report)
Time Frame: 3 months and 12 months after enrolment
The Basel Assessment of Adherence to Immunosuppressive medications (BAASIS) will be sent electronically by self-reported survey. An answer of 'yes' to any of the questions (pertaining to missing doses, drug holidays, timing, and dose reduction) will constitute non-adherence as a binary outcome. • A continuous measure of adherence will also be determined in each individual using a visual analogue scale.
3 months and 12 months after enrolment
Difference in adherence to immunosuppressant medications between intervention and control (immunosuppressant blood levels)
Time Frame: 3 months and 12 months after enrolment
Immunosuppressant levels (tacrolimus, cyclosporine or sirolimus) will be collected as per routine practice, and will be standardized to the patient specific target. Intra-patient coefficients of variation (CV) will be used as a measure of trough level variability, and percentage of sub-therapeutic levels will be determined for each patient.
3 months and 12 months after enrolment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in changes in kidney transplant knowledge between intervention and control
Time Frame: 3 months and 12 months after enrolment
Measured by the Kidney Transplant Understanding Tool (K-TUT) via self-reported electronic survey. The K-TUT consists of 9 true/false and 13 multiple-choice questions, and scores are based on the number correct answers [YES/ NO format] of 69 items.
3 months and 12 months after enrolment
Difference in quality of life between intervention and control
Time Frame: 3 months and 12 months after enrolment
Measured by the Short Form 12 (SF-12) via self-reported electronic survey. The SF-12 is a 12-item psychometric scale that measures functional health and well-being. Responses are indicated on a likert scale and aggregated into two sub scales; the mental component summary (MCS) and the physical component summary (PCS). The scores are converted to adjusted norm-based values of a healthy individual with a midpoint score of 50 indicating average health comparable to norm values.
3 months and 12 months after enrolment
Difference in self efficacy between intervention and control
Time Frame: 3 months and 12 months after enrolment
Measured by the Generalized Self-Efficacy Scale (GSE) via self-reported electronic survey. The GSE measures an individual's self-beliefs in their ability to cope with various demands in life. It is a 10-item psychometric scale with a score for each item ranging from 1 to 4. The scores are summed and a higher score indicates stronger patient beliefs in self-efficacy.
3 months and 12 months after enrolment
Difference in education satisfaction between intervention and control
Time Frame: 3 months and 12 months after enrolment
Measured by self-report electronic survey
3 months and 12 months after enrolment
Difference in beliefs about medication between intervention and control
Time Frame: 3 months and 12 months after enrolment
Measured by the Beliefs of Medicine Questionnaire (BMQ) via self-reported electronic survey. The BMQ is an 18-item psychometric questionnaire which consists of two subscales. The BMQ-Specific assesses perceptions of medication prescribed for personal use, while the BMQ-General assesses beliefs about medications in general. The BMQ-General can be further classified into domain of General-Harm and General-Overuse. Items are scored on a 5-point likert scale, with higher score indicating stronger beliefs in each subscale.
3 months and 12 months after enrolment
Difference in adherence to transplant appointments between intervention and control
Time Frame: study end (12 months after enrolment)
Captured by chart review
study end (12 months after enrolment)
Video viewing habits (duration of viewing time)
Time Frame: study end (12 months after enrolment)
We will record the total duration that participants have watched each video (in minutes). This number will be divided by the total length of each video and used as a surrogate marker for whether each video was watched in its entirety.
study end (12 months after enrolment)
Cost of administering the intervention
Time Frame: study end (12 months after enrolment)
Staff time and other resources used in administering the intervention will be tracked and monetized using market wages and prices.
study end (12 months after enrolment)
Days in hospital
Time Frame: study end (12 months after enrolment)
The number of days in hospital will be collected by chart review at the end of the study period to estimate health care utilization.
study end (12 months after enrolment)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2018

Primary Completion (Actual)

December 31, 2022

Study Completion (Actual)

December 31, 2022

Study Registration Dates

First Submitted

April 27, 2018

First Submitted That Met QC Criteria

May 25, 2018

First Posted (Actual)

May 30, 2018

Study Record Updates

Last Update Posted (Actual)

August 16, 2024

Last Update Submitted That Met QC Criteria

August 14, 2024

Last Verified

August 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 99399

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe